Quadratus Lumborum Block During Minimally Invasive Colorectal Surgery: A Tool for Enhanced Recovery
Listen to this summary
The authors aimed to evaluate the efficacy of the quadratus lumborum block in conjunction with the transversus abdominis plane block compared to other regional anesthetic techniques in patients undergoing minimally invasive colorectal surgery. Their findings suggest that the combined block is associated with lower postoperative pain scores, reduced opioid requirements on postoperative day 2, and a shorter length of hospital stay, indicating its potential benefits in enhancing recovery. The study highlights the need for further randomized trials to confirm these outcomes.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More in Colon & Rectal Surgery
View all →Aug 6, 2026 · Lancet (London, England)
[<sup>177</sup>Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Aug 5, 2026 · The New England journal of medicine
Syncope
Jul 31, 2026 · Lancet (London, England)
Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 29, 2026 · Lancet (London, England)
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
